Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1984-4-4
|
| pubmed:abstractText |
In a single-blind test vs placebo in two crossover therapy phases, each lasting 4 weeks, it was shown in six clinical cases of hyperkinetic heart syndrome that 2 X 2.5 mg mepindolol sulfate daily is able to (1) lower significantly the HR and the systolic BP at rest and during exercise on the ergometer, (2) normalize or increase by 100% the restricted effective working capacity, and (3) improve the subjective symptoms. Mepindolol sulfate can accordingly be regarded as an effective therapeutic agent in hyperkinetic heart syndrome.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0174-4879
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
22
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
42-4
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
1984
|
| pubmed:articleTitle |
Mepindolol sulfate in the hyperkinetic heart syndrome.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|